Stocks/TSX/BLCO

Bausch + Lomb Corp (BLCO : TSX)

Common Stock

$21.63

CAD

+0.56 (2.66%)

Last updated: 2026-06-23

BLCO

Bausch + Lomb Corp

Source:WealthAwesomeWealthAwesome
โ†“ $0.33 (-1.50%)
30 day period
$20.60$21.45$22.30May 12Jun 3Jun 23

Performance

1 Day

+2.66%

1 Week

+2.85%

1 Month

-1.50%

YTD

-5.09%

Key Statistics

Market Cap

$7.71B

52W High

$25.70

52W Low

$16.48

P/E Ratio

-

50 Day MA

$21.74

200 Day MA

$22.30

Beta

0.57

Dividend Yield

-

Technical Indicators

Price vs 50-Day SMA

โ†“Below 50 SMA

Price vs 200-Day SMA

โ†“Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
6/23/2026$21.21$21.68$21.21$21.63$21.631,902
6/22/2026$20.96$21.39$20.96$21.07$21.076,912
6/19/2026$21.05$21.05$20.61$20.61$20.61300
6/18/2026$21.00$21.11$21.00$21.04$21.04500
6/17/2026$20.96$21.13$20.69$21.07$21.072,302
6/16/2026$20.95$21.16$20.94$21.03$21.03604
6/15/2026$21.04$21.47$20.84$20.87$20.871,187
6/12/2026$21.22$21.22$21.10$21.10$21.10521
6/11/2026$21.80$21.80$21.10$21.29$21.291,180
6/10/2026$20.57$21.65$20.57$21.28$21.281,201

Analyst Price Targets

Based on analyst covering BLCO

๐Ÿ“‰

Wall Street analysts forecast BLCO stock price to fall 12.1% over the next 12 months.

Consensus

No Rating

Avg. Target

C$19.01

-12.1% Upside

Current Price

C$21.63

Last close

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on BLCO's historical volatility

HistoricalForecast68%95%
C$16.15C$18.97C$21.80C$24.62C$27.45C$30.27TodayFeb 13Apr 21Jun 23Aug 5Sep 18Oct 31

30-Day Vol

23.8%

Annualized

90-Day Vol

29.9%

Annualized

Trend (90d)

+6.3%

Annualized drift

90d Mean

C$22.12

Expected price

HorizonExpected68% Range (1ฯƒ)
30 trading daysC$21.79C$20.08 โ€“ C$23.65
60 trading daysC$21.95C$19.55 โ€“ C$24.66
90 trading daysC$22.12C$19.19 โ€“ C$25.50

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯƒ, 95% band = ยฑ2ฯƒ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Bausch + Lomb Corp

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Financials

Revenue (TTM)
$5.21B
EBITDA
$724.00M
Profit Margin
-4.21%
ROE (TTM)
-3.28%
EPS (Diluted)
-0.88
Book Value
25.37

Classification

Sector
Health Care
Industry
Health Care Equipment & Supplies
Group
Health Care Equipment & Services

Advertisement

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Common Questions About BLCO

Articles Featuring BLCO.TO

Latest articles and analysis covering BLCO.TO

Why Bausch + Lomb Corp stock is rising today

Bausch + Lomb Corp's stock rose by 2.66% in the latest trading session, reflecting positive investor sentiment amid ongoing developments in the optical health industry.

โ€ขStocks
Why Bausch + Lomb Corp stock is rising today

Why Bausch + Lomb Corp stock is rising today

Bausch + Lomb Corp's stock rose 2.04% in the last session, driven by strategic advancements and partnerships aimed at enhancing its ophthalmic product offerings.

โ€ขStocks
Why Bausch + Lomb Corp stock is rising today

Why Bausch + Lomb Corp stock is rising today

Bausch + Lomb Corp's stock rose 3.06% in the last trading session, closing at CA$21.24, fueled by strategic developments in the ophthalmic sector.

โ€ขStocks
Why Bausch + Lomb Corp stock is rising today

Why Bausch + Lomb Corp stock is sliding today

Bausch + Lomb Corp's stock fell by 2.04% today, closing at CA$20.61. Investors are reacting to the company's financial metrics and recent strategic investments, highlighting concerns over its profitability and market position.

โ€ขStocks
Why Bausch + Lomb Corp stock is sliding today

Why Bausch + Lomb Corp stock is rising today

Bausch + Lomb Corp's stock surged by 3.22% in the last trading session, buoyed by strong financial results and an optimistic outlook for the year ahead.

โ€ขStocks
Why Bausch + Lomb Corp stock is rising today

Bausch + Lomb Corp. (BLCO.TO) Faces Pressure After Last Session's Decline

Bausch + Lomb Corp. faced a significant decline in share price during the last session, with no recent news to clarify the downturn.

โ€ขStocks
Bausch + Lomb Corp. (BLCO.TO) Faces Pressure After Last Session's Decline

Why Bausch + Lomb Corp stock is sliding today

Bausch + Lomb Corp's stock fell 2.50% today, closing at CA$21.10. This decline comes despite the company's recent product launch aimed at addressing dry eye symptoms, raising concerns about its market performance.

โ€ขStocks
Why Bausch + Lomb Corp stock is sliding today

7 Best Healthcare Stocks In Canada to Buy In June 2026

A decent number of sources place Canada's healthcare system among the top ten in the world. Most of the 1,200 hospitals in Canada are publicly funded, and only a tiny number are purely for-profit. With this level of public funding and ownership, the healthcare industry landscape (from an investment

โ€ขInvest
7 Best Healthcare Stocks In Canada to Buy In [currentmonthyearfull]

Advertisement